In today’s briefing:
- Thematic Report: Indian Air Conditioner Industry: The Summer That Tested India’s Cooling Story
- APAC Healthcare Weekly (October 12) – InnoCare, Daiichi Sankyo, Celltrion, Mesoblast, Lupin
Thematic Report: Indian Air Conditioner Industry: The Summer That Tested India’s Cooling Story
- The weak monsoon has slowed AC sales, leading to an excess of inventory. This disruption has caused delays in sales cycles, resulting in inventory challenges for dealers and manufacturers.
- While festive demand and lower prices may boost sales, competition remains fierce, and margins are under pressure. Manufacturers face challenges in maintaining profitability amidst shifting market dynamics.
- The industry is transitioning, influenced by policy changes, weather shifts, and evolving consumer preferences. These factors are reshaping demand and will significantly impact the market’s growth in the future.
APAC Healthcare Weekly (October 12) – InnoCare, Daiichi Sankyo, Celltrion, Mesoblast, Lupin
- InnoCare Pharma granted global rights to Zenas BioPharm to develop and commercialize an experimental drug, orelabrutinib for multiple sclerosis and other autoimmune conditions. The deal is worth of $2B+.
- Daiichi Sankyo submitted application for additional indication of Enhertu as first-line therapy for HER2 positive breast cancer in Japan. Celltrion got FDA clearance for its Eylea biosimilar, Eydenzelt.
- Mesoblast announced gross revenue of $22M from Ryoncil for the quarter ended September 30, 2025, up 66% QoQ. Lupin will invest $250M for new pharmaceutical manufacturing plant in Florida.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
